MBX Biosciences logo

MBX Biosciences

MBX | NASDAQ
Chart Builder DCF Calculator
$53.12
-$2.82 (-5.04%)
At close: Nov 16, 2026, 4:00 PM ET
$53.12
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-5.04%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
29
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #835/1021 (Top 82%)

Key Statistics

Market Data

Market Cap $2.64B
1D Range
52.90 56.76
52W Range
25.61 70.70

Valuation (TTM)

PE -17.36
PB 5.58
EV/EBITDA -14.53

Valuation (NTM)

Forward PE N/A
Forward PEG -0.47
Price Target $88.00
Loading financial charts...

Profile

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advance...

Sector Healthcare
Industry Biotechnology
Employees 63
IPO Date Sep 13, 2024
Website mbxbio.com
Fiscal Year January - December

Latest News

MBX Biosciences to Participate in Upcoming November Investor Conferences

1 month ago · globenewswire.com

MBX Biosciences to Participate in Upcoming November Investor Conferences
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)

2 months ago · seekingalpha.com

MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
MBX Biosciences to Participate in Upcoming Investor Conferences

2 months ago · globenewswire.com

MBX Biosciences to Participate in Upcoming Investor Conferences
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

2 months ago · globenewswire.com

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

3 months ago · globenewswire.com

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth

4 months ago · globenewswire.com

MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

4 months ago · seekingalpha.com

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

5 months ago · seekingalpha.com

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease

5 months ago · benzinga.com

MBX Biosciences Highlights Sustained Calcium Control In Rare Disease

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$88.00
Upside
+65.66%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.